Drugs / TSC-202-A0201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05973487 | May 2024 → Dec 2026 expected | adenosquamous carcinoma, anal squamous cell carcinoma, anogenital human papillomavirus infection, endocervical adenocarcinoma +8 | TScan Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSC-202-A0201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05973487 ↗ |